Piper Sandler & Co’s Alaunos Therapeutics TCRT Stock Holding History

Piper Sandler & Co’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-228	Closed	-$64K	–	16
2018 Q4	$64K	Buy	+228	New	+$90.1K	0.07%	9

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Piper Sandler & Co's TCRT Position: Q1 2019 in Review

Piper Sandler & Co sold out of Alaunos Therapeutics (TCRT) in Q1 2019, closing a stake of 228 shares — an estimated $64K sold.

Piper Sandler & Co first reported a position in TCRT in Q4 2018 and held it in 1 quarter. The position peaked at $64K in Q4 2018. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2019.

Piper Sandler & Co reported no remaining Alaunos Therapeutics position as of Q1 2019 after selling out during the quarter.
Piper Sandler & Co sold 228 Alaunos Therapeutics shares in Q1 2019, an estimated $64K.
Piper Sandler & Co first reported a position in Alaunos Therapeutics in Q4 2018 and held it in 1 quarter.
Piper Sandler & Co's Alaunos Therapeutics position peaked at $64K in Q4 2018.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2019.

Based on Piper Sandler & Co's 13F filing for Q1 2019, filed 15 May 2019.